News | March 12, 2024
AbCellera and Biogen collaborate on neurological antibody therapy
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
AbCellera will receive an upfront payment and is eligible to receive additional milestone payments
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Automated parallel capillary electrophoresis system simplifies protein analysis
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
One thousand times more soluble than L-cystine at neutral pH
Subscribe To Our Newsletter & Stay Updated
